# A Study to Compare MitoQ and Placebo to Treat Non-alcoholic Fatty Liver Disease (NAFLD)

> **NCT01167088** · PHASE2 · TERMINATED · sponsor: **Antipodean Pharmaceuticals, Inc.** · enrollment: 110 (estimated)

## Conditions studied

- Non-alcoholic Fatty Liver Disease

## Interventions

- **DRUG:** Mitoquinone mesylate
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01167088
- **Lead sponsor:** Antipodean Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-11
- **Primary completion:** 2011-06
- **Final completion:** 2011-07
- **Target enrollment:** 110 (ESTIMATED)
- **Why stopped:** This study has been terminated due to poor participant recruitment
- **Last updated:** 2011-06-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01167088

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01167088, "A Study to Compare MitoQ and Placebo to Treat Non-alcoholic Fatty Liver Disease (NAFLD)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01167088. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*